P335: Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel diseaseECCO '17 Barcelona
2017
P336: Safety of anti-TNF treatment in older IBD patients: a systematic review and meta-analysisECCO '17 Barcelona
2017
P337: Efficacy of intravenous cyclosporine in fulminant steroid-refractory ulcerative colitis with massive bleeding: a retrospective, observational studyECCO '17 Barcelona
2017
P338: Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversalECCO '17 Barcelona
2017
P339: MadCAM1 expression in intestinal lamina propria endothelium varies among inflammatory bowel disease patientsECCO '17 Barcelona
2017
P340: Prevalence and long-term effect of antiplatelet use in inflammatory bowel diseaseECCO '17 Barcelona
2017
P341: Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practiceECCO '17 Barcelona
2017
P342: Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel diseaseECCO '17 Barcelona
2017
P343: Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBDECCO '17 Barcelona
2017
P344: Vitamin D-Induced alterations in Cytokine levels lower the risk of clinical relapse in ulcerative colitisECCO '17 Barcelona
2017
P345: Inconsistency between electronic data of patient's adherence and self reported adherence scoreECCO '17 Barcelona
2017
P346: Dietary practices and beliefs among parents of children with inflammatory bowel disease: preliminary resultsECCO '17 Barcelona
2017
P347: Evaluation of step up therapy in patients with early ulcerative colitis: a prospective cohort studyECCO '17 Barcelona
2017
P348: Persistent hyperCKemia during infliximab therapy in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P349: The therapies influencing postoperative surgical recurrence in Crohn's diseaseECCO '17 Barcelona
2017
P350: Induction of antiphospholipid antibodies in patients with inflammatory bowel disease treated with anti-TNFα agentsECCO '17 Barcelona
2017
P351: Do self-selected “Non-Transitioned” referrals from peadiatric services have lower treatment requirements?ECCO '17 Barcelona
2017
P352: Assessment of the use of therapeutic drug monitoring of Adalimumab during maintenance therapy in children with inflammatory bowel diseaseECCO '17 Barcelona
2017